Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $126.00.

A number of analysts have recently commented on the company. JMP Securities cut their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Leerink Partners raised their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Redburn Atlantic began coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. Finally, Truist Financial decreased their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $109.38 on Thursday. Lantheus has a one year low of $50.20 and a one year high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The company has a market cap of $7.58 billion, a price-to-earnings ratio of 16.70 and a beta of 0.50. The firm has a 50 day simple moving average of $107.80 and a 200 day simple moving average of $93.85.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The firm’s revenue was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.40 earnings per share. Research analysts predict that Lantheus will post 5.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now directly owns 98,980 shares in the company, valued at approximately $9,540,682.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,981 shares of company stock valued at $2,689,156. 1.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Signaturefd LLC increased its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares in the last quarter. GAMMA Investing LLC grew its position in Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 208 shares during the period. UMB Bank n.a. increased its stake in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in Lantheus during the third quarter worth $51,000. Finally, Fidelis Capital Partners LLC bought a new position in shares of Lantheus in the first quarter valued at $34,000. 99.06% of the stock is owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.